Hytale started the new year off by showcasing some of the PvP action players can expect to find when the game launches into Early Access later this month. The video, which was posted to the team's ...

Mamady Doumbouya took power in 2021 coup Former special forces commander reversed pledge not to run Guinea is home to newly launched Simandou iron ore mega mine CONAKRY, Dec 30 (Reuters) - Guinea coup ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion Pharmaceuticals announced positive Phase 1b/2 results from its ongoing TUPELO trial ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...

For one last time in 2025, WWE SmackDown aired, and it was also the final two-hour edition before the show expands to three hours in 2026. The results from the test run earlier this year were not ...

AUSTIN (KXAN) — After years of requests from the community and Travis County leaders, Central Health and Dell Medical School have released data on how their taxpayer-funded partnership is working for ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. ORLANDO — In this video from the American Academy of ...

EXCLUSIVE: President Donald Trump’s return to the White House has brought a surge in media access following the Biden administration, with hundreds of direct exchanges between a press corps he ...

New research is challenging one of medicine’s oldest assumptions: that cancer must be attacked to be cured. By treating glioblastoma patients with a simple combination of resveratrol and copper, the ...

A new experimental scalp treatment called clascoterone has shown strong results in helping reduce male-pattern hair loss (also known as androgenetic alopecia, or AGA). Experts call the results ...

Lisocabtagene maraleucel (liso-cel), a CAR T cell therapy, achieved an overall response rate of 97% in the TRANSCEND FL study Durable benefits persisted at three years and showed a favorable long-term ...